Community Schedule

Enter at least 4 characters

1 results showing for: 'bexsero'

- Only on a prescription
- No patient co-payment payable
  • Inj 175 mcg per 0.5 ml prefilled syringe
    • Brand Fully subsidised brand. Bexsero
    • Pharmacode2556251
    • Subsidy $0.00
    • Measure / Qty per 1
    • Brand Fully subsidised brand. Bexsero
    • Pharmacode2669668
    • Subsidy $0.00
    • Measure / Qty per 1
    • Brand Fully subsidised brand. Bexsero
    • Pharmacode2671948
    • Subsidy $0.00
    • Measure / Qty per 10

Any of the following:

  1. Three doses for children up to 12 months of age (inclusive) for primary immunisation; or

  2. Up to three doses (dependent on age at first dose) for a catch-up programme for children from 13 months to 59 months of age (inclusive) for primary immunisation, from 1 March 2023 to 31 August 2025; or

  3. Both:

    1. Person is one year of age or over; and

    2. Any of the following:

      1. up to two doses and a booster every five years for patients pre- and post-splenectomy and for patients with functional or anatomic asplenia, HIV, complement deficiency (acquired or inherited), or pre- or post-solid organ transplant; or

      2. up to two doses for close contacts of meningococcal cases of any group; or

      3. up to two doses for person who has previously had meningococcal disease of any group; or

      4. up to two doses for bone marrow transplant patients; or

      5. up to two doses for person pre- and post-immunosuppression*; or

  4. Both:

    1. Person is aged between 13 and 25 years (inclusive); and

    2. Either:

      1. Two doses for individuals who are entering within the next three months, or in their first year of living in boarding school hostels, tertiary education halls of residence, military barracks, Youth Justice residences or prisons; or

      2. Two doses for individuals who turn 13 years of age while living in boarding school hostels.

  5. Contractors will be entitled to claim payment from the Funder for the supply of Meningococcal B multicomponent vaccine to patients eligible under the above criteria pursuant to their contract with Te Whatu Ora Health New Zealand for subsidised immunisation, and they may only do so in respect of the Meningococcal B multicomponent vaccine listed in the Pharmaceutical Schedule.

  6. Contractors may only claim for patient populations within the criteria that are covered by their contract, which may be a sub-set of the population described in paragraphs A-D above.

*Immunosuppression due to corticosteroid or other immunosuppressive therapy must be for a period of greater than 28 days.

  • Rectangle page icon symoblising a PDF. PDF
  • A tick icon. Fully subsidised
  • An oval with the number 29 in it. Unapproved medicine under Section 29
  • An asterisk symbol. 3 or 6 months should be dispensed at once
  • Two duplicate pages icon. Click to copy
  • A triangle symbol. Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.
  • OP Original pack
  • Sole Subsidised Supply